PMID- 29374696
OWN - NLM
STAT- MEDLINE
DCOM- 20180208
LR  - 20220330
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 2
DP  - 2018 Feb
TI  - SATB1 Level Correlates with Ki-67 Expression and Is a Positive Prognostic Factor 
      in Non-small Cell Lung Carcinoma.
PG  - 723-736
AB  - BACKGROUND: Non-small cell lung carcinomas (NSCLCs), mainly adenocarcinoma (AC) 
      and squamous cell carcinoma (LSCC), account for about 80% of all lung cancer 
      cases. One of the proteins involved in NSCLC progression may be special AT-rich 
      binding protein 1 (SATB1), a potent transcriptional regulator, able to control 
      the expression of whole sets of genes simultaneously. SATB1 has been found to be 
      associated with aggressive phenotype and poor prognosis in numerous malignancies, 
      including breast, colon, ovary and prostate cancer. However, its role in NSCLC is 
      still not fully understood. The aim of this study was to investigate the 
      expression of SATB1 protein and mRNA in NSCLC and non-malignant lung tissue 
      (NMLT) samples, as well as to determine possible relationships of SATB1 
      expression with both the expression of Ki-67 and the clinicopathological data of 
      the patients. MATERIALS AND METHODS: The study was performed on 277 NSCLC (158 
      AC, 119 LSCC) and 20 NMLT samples. RESULTS: We observed increased SATB1 
      immunoreactivity in NSCLC when compared to NMLT, and in LSCC when compared to AC 
      cases. We also noted that an elevated SATB1 immunoreactivity was associated with 
      a poor degree of AC differentiation, whereas in LSCC, an inverse relationship was 
      observed. Our analyses revealed that the expression of SATB1 positively 
      correlated with Ki-67 index in NSCLC and LSCC, but not in AC cases. Finally, we 
      found that high SATB1 expression was associated with a better overall survival of 
      patients with NSCLC. CONCLUSION: SATB1 plays diverse roles in different NSCLC 
      subtypes, and its expression may have a prognostic significance for patients with 
      these tumours.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Glatzel-Plucinska, Natalia
AU  - Glatzel-Plucinska N
AD  - Department of Histology and Embryology, Medical University, Wroclaw, Poland.
FAU - Piotrowska, Aleksandra
AU  - Piotrowska A
AD  - Department of Histology and Embryology, Medical University, Wroclaw, Poland.
FAU - Grzegrzolka, Jedrzej
AU  - Grzegrzolka J
AD  - Department of Histology and Embryology, Medical University, Wroclaw, Poland.
FAU - Olbromski, Mateusz
AU  - Olbromski M
AD  - Department of Histology and Embryology, Medical University, Wroclaw, Poland.
FAU - Rzechonek, Adam
AU  - Rzechonek A
AD  - Department of Thoracic Surgery, Medical University, Wroclaw, Poland.
FAU - Dziegiel, Piotr
AU  - Dziegiel P
AD  - Department of Histology and Embryology, Medical University, Wroclaw, Poland.
AD  - Department of Physiotherapy, University School of Physical Education, Wroclaw, 
      Poland.
FAU - Podhorska-Okolow, Marzenna
AU  - Podhorska-Okolow M
AD  - Department of Histology and Embryology, Medical University, Wroclaw, Poland 
      marzenna.podhorska-okolow@umed.wroc.pl.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Matrix Attachment Region Binding Proteins)
RN  - 0 (SATB1 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Carcinoma, Non-Small-Cell Lung/genetics/*metabolism/mortality/pathology
MH  - Cohort Studies
MH  - Female
MH  - Fibroblasts/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Ki-67 Antigen/*metabolism
MH  - Lung Neoplasms/genetics/*metabolism/mortality/pathology
MH  - Male
MH  - Matrix Attachment Region Binding Proteins/genetics/*metabolism
MH  - Middle Aged
MH  - Prognosis
MH  - Tissue Array Analysis
OTO - NOTNLM
OT  - AC
OT  - Ki-67
OT  - LSCC
OT  - NSCLC
OT  - SATB1
OT  - lung adenocarcinoma
OT  - lung squamous cell carcinoma
OT  - non-small cell lung carcinoma
EDAT- 2018/01/29 06:00
MHDA- 2018/02/09 06:00
CRDT- 2018/01/29 06:00
PHST- 2017/10/30 00:00 [received]
PHST- 2017/11/17 00:00 [revised]
PHST- 2017/11/23 00:00 [accepted]
PHST- 2018/01/29 06:00 [entrez]
PHST- 2018/01/29 06:00 [pubmed]
PHST- 2018/02/09 06:00 [medline]
AID - 38/2/723 [pii]
AID - 10.21873/anticanres.12278 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Feb;38(2):723-736. doi: 10.21873/anticanres.12278.